PRINCETON, N.J. & PARIS. -- STENTYS, a medical technology company commercializing the world’s first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced that the 4-month results of the APPOSITION IV trial will be disclosed during the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. Dr Robert-Jan van Geuns, M.D., Ph.D., of Erasmus MC (Rotterdam, the Netherlands) and co-Principal Investigator, will present “Sirolimus-Eluting Self-Apposing Stent: Preliminary Results of the APPOSITION IV Study and Future Developments”, during a Satellite Symposium on October 29 at 7:00am.

The Self-Apposing Stent will also be featured in multiple presentations throughout the congress, including results on series of patients outside of the AMI indication. Results of the OPEN II trial, a 200 patient European study evaluating the Self-Apposing DES in the treatment of coronary bifurcation lesions, will be presented by the Principal Investigator of the study, Dr Christoph K. Naber, M.D., Ph.D. of Contilia Heart and Vascular Center (Essen, Germany) on October 28 at 4:30pm.

Source: STENTYS